Review
Urology & Nephrology
Takafumi Yanagisawa, Pawel Rajwa, Tatsushi Kawada, Keiichiro Mori, Wataru Fukuokaya, Patrik Petrov, Fahad Quhal, Ekaterina Laukhtina, Markus von Deimling, Alberto Bianchi, Muhammad Majdoub, Benjamin Pradere, Gero Kramer, Takahiro Kimura, Shahrokh F. F. Shariat
Summary: This study analyzed and compared the efficacy of combination systemic therapies in metastatic hormone-sensitive prostate cancer and metastatic castration-resistant prostate cancer with or without visceral metastasis. It was found that adding androgen receptor signaling inhibitor to standard of care improved overall survival in patients with visceral metastasis. In metastatic hormone-sensitive prostate cancer patients, darolutamide + docetaxel + androgen deprivation therapy had the highest likelihood of improved overall survival.
JOURNAL OF UROLOGY
(2023)
Article
Urology & Nephrology
Andrew J. Armstrong, Neal D. Shore, Russell Z. Szmulewitz, Daniel P. Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Arun Azad, Antonio Alcaraz, Boris Alekseev, Taro Iguchi, Francisco Gomez-Veiga, Brad Rosbrook, Ho-Jin Lee, Gabriel P. Haas, Arnulf Stenzl
Summary: The study found that treatment with enzalutamide plus androgen deprivation therapy provides significant improvements in men with bone and/or lymph node metastases but may be less effective in men with visceral patterns of spread.
JOURNAL OF UROLOGY
(2021)
Article
Urology & Nephrology
William T. Lowrance, Rodney H. Breau, Roger Chou, Brian F. Chapin, Tony Crispino, Robert Dreicer, David F. Jarrard, Adam S. Kibel, Todd M. Morgan, Alicia K. Morgans, William K. Oh, Matthew J. Resnick, Anthony L. Zietman, Michael S. Cookson
Summary: This summary focuses on Part I of the series dedicated to Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline, providing prognostic and treatment recommendations for patients with advanced prostate cancer. The guideline includes evidence- and consensus-based statements to improve patient care, with the need for continued research to enhance treatment outcomes in the future.
JOURNAL OF UROLOGY
(2021)
Article
Urology & Nephrology
Melanie Rouleau, Bertrand Neveu, Patrick Caron, Fannie Morin, Paul Toren, Louis Lacombe, Veronique Turcotte, Eric Levesque, Chantal Guillemette, Frederic Pouliot
Summary: Testosterone and dihydrotestosterone play a significant role in prostate cancer progression and resistance. Castration reduces the levels of 15 circulating steroids, and their association with testosterone and dihydrotestosterone varies under different treatment conditions.
JOURNAL OF UROLOGY
(2022)
Article
Oncology
Pedro C. Barata, Andrea Leith, Amanda Ribbands, Rachel Montgomery, Matthew Last, Bhakti Arondekar, Jasmina Ivanova, Alexander Niyazov
Summary: The study evaluated the impact of novel hormonal therapy (NHT) and docetaxel use in metastatic castration-sensitive prostate cancer (mCSPC) on first-line treatment patterns in metastatic castration-resistant prostate cancer (mCRPC). The results suggest that physicians consider mCSPC treatment history when making first-line treatment decisions in mCRPC.
Article
Urology & Nephrology
Kathleen W. Zhang, Melissa A. Reimers, Adam Christopher Calaway, Michael G. Fradley, Lee Ponsky, Jorge A. Garcia, Jennifer Cullen, Brian C. Baumann, Daniel Addison, Courtney M. Campbell, Arjun K. Ghosh, Daniel J. Lenihan, Nihar R. Desai, Neal Weintraub, Avirup Guha
Summary: In men treated for prostate cancer, arterial vascular events were the most commonly reported cardiovascular adverse events. GnRH antagonists were associated with fewer cardiovascular adverse events compared to GnRH agonists.
JOURNAL OF UROLOGY
(2021)
Article
Urology & Nephrology
Neeraj Agarwal, Kelly McQuarrie, Anders Bjartell, Simon Chowdhury, Andrea J. Pereira de Santana Gomes, Byung Ha Chung, Mustafa Ozguroglu, Alvaro Juarez Soto, Axel S. Merseburger, Hirotsugu Uemura, Dingwei Ye, Robert Given, Ethan Basch, Branko Miladinovic, Angela Lopez-Gitlitz, Kim N. Chi
Summary: This study explored the impact of pain and fatigue on quality of life in patients with metastatic castration-sensitive prostate cancer. Patients receiving apalutamide plus ADT reported better pain outcomes, while there was no significant difference in fatigue between the treatment groups.
JOURNAL OF UROLOGY
(2021)
Article
Urology & Nephrology
Yiming Gong, Liancheng Fan, Xiaochen Fei, Yinjie Zhu, Xinxing Du, Yuman He, Jiahua Pan, Baijun Dong, Wei Xue
Summary: The study explored the genomic features of prostate cancer metastases in different sites, revealing distinct genetic profiles and alterations, including low AR alterations in pulmonary metastasis and high DNA damage response pathway deficiencies in hepatic metastasis. PTEN alterations were found to be more prevalent in viscerally metastatic prostate cancer. These findings suggest potential therapeutic targets in visceral metastatic prostate cancer.
JOURNAL OF UROLOGY
(2021)
Article
Oncology
Pedro C. Barata, Andrea Leith, Amanda Ribbands, Rachel Montgomery, Matthew Last, Bhakti Arondekar, Jasmina Ivanova, Alexander Niyazov
Summary: This study analyzed the real-world treatment trends for patients with metastatic castration-sensitive prostate cancer (mCSPC) between 2016 and 2020 in 5 European countries and the US. The results showed that more patients received treatment intensification with novel hormonal therapy and taxane chemotherapy in 2019-2020 compared to 2016-2018. In the US, greater use of treatment intensification with novel hormonal therapy was observed for all ethnicity groups and those with Medicare and commercial insurance status in 2019-2020. Further research is needed to understand optimal treatment sequencing in mCSPC and mCRPC.
Article
Urology & Nephrology
Jack R. Andrews, Mohamed E. Ahmed, Vidit Sharma, Cameron Britton, Bradley Stish, Ryan Phillips, A. Tuba Kendi, Vidhu B. Joshi, Akshay Sood, Mathew K. Tollefson, Stephen A. Boorjian, R. Jeffery Karnes, Eugene D. Kwon
Summary: This study characterizes the outcomes of metastasis-directed therapy without concurrent androgen deprivation therapy in patients with solitary metastatic lesions in prostate cancer. The results demonstrate that this approach can delay the initiation of systemic therapy and call for further prospective studies in patients with solitary recurrent prostate cancer metastases.
JOURNAL OF UROLOGY
(2022)
Article
Urology & Nephrology
Catherine Handy Marshall, Yongmei Chen, Claire Kuo, Jennifer Cullen, Jiji Jiang, Inger Rosner, Mark Markowski, David G. McLeod, Bruce J. Trock, Mario A. Eisenberger
Summary: This study retrospectively analyzed the metastasis-free survival and overall survival of men with BCR who delayed ADT treatment. The results showed that patients who deferred treatment had longer survival times, indicating the need to reassess when to start primary ADT in this patient population.
JOURNAL OF UROLOGY
(2021)
Review
Urology & Nephrology
Reza Sari Motlagh, Fahad Quhal, Keiichiro Mori, Noriyoshi Miura, Abdulmajeed Aydh, Ekaterina Laukhtina, Benjamin Pradere, Pierre I. Karakiewicz, Dmitry V. Enikeev, Marina Deuker, Shahrokh F. Shariat
Summary: This study found that men with prostate cancer who received androgen deprivation therapy have a higher risk of developing dementia and/or Alzheimer's disease compared to those who did not receive the therapy, especially when the therapy lasted for more than 12 months.
JOURNAL OF UROLOGY
(2021)
Article
Urology & Nephrology
Samuel Tremblay, Lily Summers-Trasiewicz, Frederic Pouliot, Juanita M. Crook, Keyue Ding, Laurence Klotz, Paul Toren
Summary: This study aimed to evaluate the relationship between testosterone levels and PSA levels during ADT and its impact on clinical outcomes. The results showed that testosterone levels had a smaller prognostic effect compared to PSA levels on outcomes. Specifically, there was no significant association between the cumulative testosterone exposure and outcomes.
JOURNAL OF UROLOGY
(2021)
Article
Oncology
Daniel J. Herr, David A. Elliott, Gillian Duchesne, Kristian D. Stensland, Megan E. V. Caram, Christina Chapman, Jennifer A. Burns, Brent K. Hollenbeck, Jordan B. Sparks, Chris Shin, Alexander Zaslavsky, Alexander Tsodikov, Ted A. Skolarus
Summary: This study aims to examine the 10-year clinical outcomes of patients with localized prostate cancer undergoing radiation therapy within a national healthcare system. The results showed improved survival rates for high-risk disease, providing important benchmarks for clinical decision-making.
Article
Urology & Nephrology
Charles J. Ryan, Xuehua Ke, Marie-Helene Lafeuille, Hela Romdhani, Frederic Kinkead, Patrick Lefebvre, Allison Petrilla, Zul Pulungan, Seung Kim, Denise M. D'Andrea, Peter Francis, Stephen J. Freedland
Summary: This study provides a contemporary assessment of the treatment patterns, health care resource utilization, and costs among metastatic castration-sensitive prostate cancer patients in the U.S. The study found limited use of newer therapies that improve survival in men with mCSPC in the U.S., and substantial increases in health care resource utilization and costs after onset of metastasis.
JOURNAL OF UROLOGY
(2021)